

CompuSyn Report Examples

A. Drug Combination *in Vitro*: Sample CompuSyn Report

Experimental design and data analysis using the combination index method

**“Synergistic Combination of Anti-cancer
Fludelone with Cyto-protective Panaxytriol
against MX-1 Cells *in Vitro*”**

Zhang N, Fu JN and Chou TC
Am. J. Cancer Res. 6: 97-104, 2016
[For details and Discussions, see original article]

[The author's notes are added in the shaded areas on right-side-margin of the CompuSyn Report]

CompuSyn Report

The analysis usually takes about 1 sec. Printing may take about 1 min.

The report contents depend on the selections at the "Generate Report" command in the menu.

Do not use "polygonogram" since it is for ≥ 3 drug combos

Experiment

Name: FD+PXT in MX-1 in Vitro

Date: 9. 15. 2015 *Remove "*" in front of *. cse when give file name for saving*

File Name: C:\Users\TingChaoChou\Desktop\FD.PXT.MX1. 9.15. 2015.cse

Description: Combination of Fludelone (PD) and Panaxytriol (PXT) in Vitro against Mammary Cancer MX-1 Cell Growth, XTT assays

Drug: Fludelone (FD) [nM] *Can be different units. InM:1 μ M in this case.*

Drug: Panaxytriol (PXT) [μ M] *If both in μ M, then the ratio is 1:1000*

Drug Combo: Fludelone + Panaxytriol (FD+PXT) (FD+PXT [1:1])

Data for Drug: FD [nM]

Dose Effect

| | |
|-------|--------|
| 0.05 | 0.0842 |
| 0.125 | 0.1208 |
| 0.25 | 0.2204 |
| 0.5 | 0.2222 |
| 1.25 | 0.3584 |
| 2.5 | 0.4531 |
| 5.0 | 0.6309 |
| 12.5 | 0.7308 |

8 data points entered.

X-int: 0.43522

Y-int: -0.2693 +/- 0.02517

m: 0.61871 +/- 0.03242 *The "slope" of the median-effect (ME) plot, the dynamic order, or the "shape" of dose-effect curve; m=1, >1 and <1 indicate hyperbolic, sigmoidal and flat sigmoidal shape, respectively.*

Dm: 2.72408 *Dm: The median effect dose, in this case it is IC₅₀ value, which indicates "potency". The value can be obtained from the X-intercept of the ME-plot*

r: 0.99186 *r: The linear correlation coefficient of the ME-plot. It signifies the "conformity" of the data with the mass-action law; an indication of how good are the data, when r=1, it is perfect; For in vitro experiment, usually r>0.95 are considered good or acceptable*

Data points usually from the average Fa values of duplicate or triplicate assays

Design Dose Range: Some doses above Dm, and some doses below the Dm value (e.g. here Dm=2.724nm);

The approximate Dm value can be from the preliminary data or from published literature

*Do not enter fa <0.01 or Fa >0.99, unless the assay is very accurate
If enter fa=0 or fa=1, the computer will crash*

Data for Drug: PXT [μ M]

Dose Effect

1.25 0.1305

2.5 0.2697

5.0 0.6349

12.5 0.9812

25.0 0.9949

50.0 0.9993

6 data points entered. \longrightarrow

X-int: 0.50391

Y-int: -1.3101 +/- 0.16663

m: 2.59980 +/- 0.15768

Dm: 3.19086

r: 0.99272

D₁ has 8 doses (concentrations), and D₂ has 6 concentrations, not the same number is OK as long as they provide m₁, (Dm)₁, m₂, and (Dm)₂ values from the dose-effect curves; In most cases, such as 5 vs 5, 6 vs 6 for D₁ and D₂ are OK.

The m₁, (Dm)₁ as well as m₂, (Dm)₂ are absolute requirements for determining synergism or antagonism or additive effect since they are required for the calculation of the CI value

Data for Drug Combo: FD+PXT (FD+PXT [1:1])

Dose A Effect

0.5+ 0.3218

1.25+ 0.5136

2.5+ 0.6332

5.0+ 0.8777

12.5+ 0.9786

25.0+ 0.9943

50.0+ 0.9995

7 data points entered.

X-int: 0.39023

Y-int: -0.6992 +/- 0.22052

m: 1.79184 +/- 0.18016

Dm: 2.45601

r: 0.97565

In this case 1:1 means FD 0.5nM+PXT 0.5uM, etc

[NOTES]

Recommend to make a 1:1 mixture, and serial dilution them; Do not do more than 2-fold or 3-fold serial dilutions, otherwise the dose-range would be too large for the accurate measurements of effects.

The constant ratio combination allows computerized simulation of dose-effect curves, Fa-CI effect, Fa-DRI Plot, and isobologram based on the m_{1,2} and (Dm)_{1,2} values.

When combinations are at non-constant ratios, each "data point" has a ratio, the CI and DRI value can still be calculated, but automated computer simulation can't be carried out; therefore, the acquired conclusions are limited.

[NOTES for manual calculation using a pocket calculator]

From the above Report, we obtain:

$$m_1=0.61871, \quad (Dm)_1=2.72408nM; \\ m_2=2.59980, \quad (Dm)_2=3.19086\mu M; \\ m_{1,2}=1.79184, \quad (Dm)_{1,2}=2.45601(1:1)=1.288nM+1.288\mu M$$

All parameters are calculated from the median-effect principle and equation of the mass-action law $f_a/f_u = (D/D_m)^m$ or $D = D_m [f_a/(1-f_a)]^{1/m}$ (Chou equation)
 $\log(f_a/f_u) = m \log(D) - m \log(D_m)$

Thus, the Median-effect Plot (MEP): $x = \log(D)$ $y = \log(f_a/f_u)$ gives the slope m , and the x-intercept $\log D_m$, then the antilog of the X-intercept gives the D_m value.

Based on the Combination index Theorem (CIT) and the Median-Effect Equation and Plot, when the combination $(D)_{1,2}$ for $(D)_1$ and $(D)_2$ is P/Q , we got :

$$CI = \frac{(D)_1}{(D_x)_1} + \frac{(D)_2}{(D_x)_2} = \frac{(D)_{1,2} [P/(P+Q)]}{(D_m)_1 [f_a/(1-f_a)]^{1/m_1}} + \frac{(D)_{1,2} [Q/(P+Q)]}{(D_m)_2 [f_a/(1-f_a)]^{1/m_2}}$$

Therefore, substituting, the m and D_m parameters, combination ratio P/Q into the corresponding equations given above, and setting $f_a=0.01-0.99$, the CI values at all effect levels can be simulated as $Fa-CI$ table or $Fa-CI$ Plot. The default setting for the CompuSyn is $f_a=0.05, 0.1, 0.15...0.95$ and 0.97


Based on the dose-reduction index (DRI) equations:

$$(DRI)_1 = \frac{(D_x)_1}{(D)_1}, \quad (DRI)_2 = \frac{(D_x)_2}{(D)_2}$$

$$(DRI)_1 = \frac{(D_m)_1 [f_a/(1-f_a)]^{1/m_1}}{(D)_1}, \quad (DRI)_2 = \frac{(D_m)_2 [f_a/(1-f_a)]^{1/m_2}}{(D)_2}$$

Similarly, $(DRI)_1$ and $(DRI)_2$ values at a particular combination data point can be determined or at different f_a value can be simulated.


Dose-Effect Curve



[NOTES]
Due to automated scaling, the dose-effect curves are somewhat jammed.

But they are clearly separated after linearization by the media-effect plot (see below)

Median-Effect Plot (Chou Plot)



[NOTES]
The slope (m) signifies the shape;

The x-intercept ($\log D_m$) signifies the potency (the antilog gives the D_m value)

CI Data for Drug Combo: FD+PXT (FD+PXT [1:1])

| Fa | CI Value | Total Dose |
|-----------|-----------------|-------------------|
| 0.05 | 10.3965 | 0.47487 |
| 0.1 | 4.87333 | 0.72058 |
| 0.15 | 3.11063 | 0.93284 |
| 0.2 | 2.25725 | 1.13300 |
| 0.25 | 1.75974 | 1.33032 |
| 0.3 | 1.43726 | 1.53062 |
| 0.35 | 1.21357 | 1.73857 |
| 0.4 | 1.05105 | 1.95865 |
| 0.45 | 0.92913 | 2.19580 |
| 0.5 | 0.83565 | 2.45601 |
| 0.55 | 0.76303 | 2.74706 |
| 0.6 | 0.70641 | 3.07967 |
| 0.65 | 0.66262 | 3.46952 |
| 0.7 | 0.62968 | 3.94088 |
| 0.75 | 0.60660 | 4.53425 |
| 0.8 | 0.59342 | 5.32393 |
| 0.85 | 0.59185 | 6.46626 |
| 0.9 | 0.60745 | 8.37107 |
| 0.95 | 0.66132 | 12.7024 |
| 0.97 | 0.71467 | 17.0902 |


[NOTES]
CI < 1, = 1, and > 1 indicates synergism, additive effect and antagonism, respectively.
This is Fa-CI table with Fa increment of 0.05.
At fa > 0.45 showed synergistic effect (CI < 1).
For anti-cancer agents, synergism (CI < 1) at high dose (high effect) is more relevant to the therapy than the CI values at low dose (low effect).

CI values for actual experimental points:

| Total Dose | Fa | CI Value |
|-------------------|-----------|-----------------|
| 1.0 | 0.3218 | 0.82116 |
| 2.5 | 0.5136 | 0.80387 |
| 5.0 | 0.6332 | 1.01482 |
| 10.0 | 0.8777 | 0.81016 |
| 25.0 | 0.9786 | 0.90988 |
| 50.0 | 0.9943 | 1.07814 |
| 100.0 | 0.9995 | 0.84229 |

The CI values for each individual combination data point without a simulation



Combination Index Plot



[NOTES]
 Among 7 combination data points 5 of them are on the synergism side ($CI < 1$), the other 2 points are nearly additive

The simulation at low f_a showed substantial antagonism. This is of less concern since CI values for synergism is 0-1, and for antagonism is 1- ∞ ; low f_a is less relevant to therapy than high f_a (i.e. Killing cancer cells in small fraction is not useful in cancer therapy)

Logarithmic Combination Index Plot



The logarithmic scale for CI values is to condense the graph so if there are out of scale data point can be shown

DRI Data for Drug Combo: FD+PXT (FD+PXT [1:1])

| Fa | Dose FD | Dose PXT | DRI FD | DRI PXT |
|-----------|----------------|-----------------|---------------|----------------|
| 0.05 | 0.02336 | 1.02811 | 0.09837 | 4.33008 |
| 0.1 | 0.07815 | 1.37045 | 0.21690 | 3.80375 |
| 0.15 | 0.16506 | 1.63736 | 0.35389 | 3.51047 |
| 0.2 | 0.28982 | 1.87210 | 0.51160 | 3.30468 |
| 0.25 | 0.46139 | 2.09115 | 0.69365 | 3.14384 |
| 0.3 | 0.69258 | 2.30339 | 0.90497 | 3.00974 |
| 0.35 | 1.00160 | 2.51477 | 1.15221 | 2.89292 |
| 0.4 | 1.41452 | 2.73008 | 1.44439 | 2.78772 |
| 0.45 | 1.96953 | 2.95383 | 1.79390 | 2.69044 |
| 0.5 | 2.72408 | 3.19086 | 2.21830 | 2.59841 |
| 0.55 | 3.76772 | 3.44691 | 2.74309 | 2.50953 |
| 0.6 | 5.24604 | 3.72941 | 3.40688 | 2.42195 |
| 0.65 | 7.40878 | 4.04872 | 4.27078 | 2.33388 |
| 0.7 | 10.7144 | 4.42027 | 5.43759 | 2.24329 |
| 0.75 | 16.0833 | 4.86889 | 7.09416 | 2.14761 |
| 0.8 | 25.6042 | 5.43860 | 9.61853 | 2.04308 |
| 0.85 | 44.9573 | 6.21830 | 13.9052 | 1.92331 |
| 0.9 | 94.9582 | 7.42939 | 22.6872 | 1.77501 |
| 0.95 | 317.709 | 9.90318 | 50.0234 | 1.55926 |
| 0.97 | 750.275 | 12.1503 | 87.8018 | 1.42191 |

DRI >1 and <1 indicate favorable and not favorable dose-reduction; DRI=1 indicates no dose-reduction

This is Fa-DRI table with fa increment of 0.05

At 50% inhibition, it requires 2.72408 nm of FD, and requires 3.19086µM of PXT


However, it requires 2.2183-fold less FD plus 2.5984-fold less PXT to achieve the same 50% inhibition (i.e., 1.2280nM FD+1.2280µM PXT) (1:1 combination)

DRI values calculated at experimental points

| Fa | Dose FD | Dose PXT | DRI FD | DRI PXT |
|-----------|----------------|-----------------|---------------|----------------|
| 0.3218 | 0.81643 | 2.39536 | 1.63286 | 4.79071 |
| 0.5136 | 2.97451 | 3.25835 | 2.37961 | 2.60668 |
| 0.6332 | 6.58349 | 3.93651 | 2.63340 | 1.57460 |
| 0.8777 | 65.8592 | 6.80979 | 13.1718 | 1.36196 |
| 0.9786 | 1313.82 | 13.8833 | 105.105 | 1.11066 |
| 0.9943 | 11437.1 | 23.2352 | 457.484 | 0.92941 |
| 0.9995 | 589141. | 59.3678 | 11782.8 | 1.18736 |

DRI values of each drug at each combination data point

DRI Plot for Combo: FD+PXT (FD+PXT [1:1])




○ FD
□ PXT

DRI values for FD (○) and PXT(□) are shown.

Most combinations show favorable DRI (>1).

The simulation just to show the trends.

Log(DRI) Plot for Combo: FD+PXT (FD+PXT [1:1])




The condensed log (DRI) scale

○ FD
□ PXT

Favorable DR
↕
No Dose-Reduction
↕
Not favorable DR

In this case, FD (blue circles) is very potent and toxic; Favorable dose-reduction is very beneficial to FD.

Isobologram for Combo: FD+PXT (FD+PXT [1:1])



Summary Table

Most of the contents are used for constructing Table 1 (in the article).

Experiment Name: **FD+PXT in MX-1 in Vitro**

Date: 9. 15. 2015

File Name: C:\Users\TingChaoChou\Desktop\FD.PXT.MX1. 9.15. 2015.cse

Description: Combination of Fludelone (PD) and Panaxytriol (PXT) in Vitro against Mammary Cancer MX-1 Cell Growth, XTT assays

Drug: **Fludelone (FD) [nM]**

Drug: **Panaxytriol (PXT) [uM]**

Drug Combo: FLudelone + Panaxytriol (FD+PXT) **(FD+PXT [1:1])**

| Drug/Combo | Dm | m | r |
|------------|-----------|----------|----------|
| FD | 2.72408 | 0.61871 | 0.99186 |
| PXT | 3.19086 | 2.59980 | 0.99272 |
| FD+PXT | 2.45601 | 1.79184 | 0.97565 |

For "Parameters" in Table 1

CI values at:

| Combo | ED50 | ED75 | ED90 | ED95 |
|--------|---------|---------|---------|---------|
| FD+PXT | 0.83565 | 0.60660 | 0.60745 | 0.66132 |

From the “**Fa-CI Table**” of simulation of CI values;

For numbers given in CI column of Table 1 (at bottom)

Data for Fa = 0.5

| Drug/Combo | CI value | Dose FD | Dose PXT |
|------------|----------|---------|----------|
| FD | | 2.72408 | |
| PXT | | | 3.19086 |
| FD+PXT | 0.83565 | 1.22801 | 1.22801 |

These data are illustrated for the ED₅₀-Isobologram at Fa=0.5 (in Fig. 1d)

For DRI at fa=0.5 (bottom of Table 1)
for FD=2.72408/1.22801=2.2183
for PXT=3.19086/1.22801=2.5984

Data for Fa = 0.75

| Drug/Combo | CI value | Dose FD | Dose PXT |
|------------|----------|---------|----------|
| FD | | 16.0833 | |
| PXT | | | 4.86889 |
| FD+PXT | 0.60660 | 2.26713 | 2.26713 |

For ED₇₅-isobologram in Fig. 1d

Data for Fa = 0.9

| Drug/Combo | CI value | Dose FD | Dose PXT |
|------------|----------|---------|----------|
| FD | | 94.9582 | |
| PXT | | | 7.42939 |
| FD+PXT | 0.60745 | 4.18553 | 4.18553 |

For ED₉₀-isobologram in Fig. 1d

Data for Fa = 0.95

| Drug/Combo | CI value | Dose FD | Dose PXT |
|------------|----------|---------|----------|
| FD | | 317.709 | |
| PXT | | | 9.90318 |
| FD+PXT | 0.66132 | 6.35121 | 6.35121 |

Synergy (CI<1) at high effect levels (e.g., at fa>0.90) is more relevant to anticancer (therapeutic) effect than the CI at low effect levels (e.g., at fa <0.3)

Data for Fa = 0.97

| Drug/Combo | CI value | Dose FD | Dose PXT |
|------------|----------|---------|----------|
| FD | | 750.275 | |
| PXT | | | 12.1503 |
| FD+PXT | 0.71467 | 8.54510 | 8.54510 |
